Fortress Biotech, Inc. SEC filings FBIO
Fortress Biotech, Inc. has 886 filings in SEC EDGAR's recent list, going back to Mar 5, 2008. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 1, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 17, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 17, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2025 | Jun 17, 2025 |
| DEFA14A | Additional proxy material | Apr 5, 2024 | — |
| DEF 14A | Proxy statement | Apr 5, 2024 | May 23, 2024 |
| DEFA14A | Additional proxy material | Aug 25, 2023 | — |
| DEF 14A | Proxy statement | Aug 25, 2023 | Oct 9, 2023 |
| PRE 14A | Preliminary proxy statement | Aug 15, 2023 | Oct 9, 2023 |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 21, 2023 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Mar 13, 2023 | Apr 10, 2023 |
| PRE 14A | Preliminary proxy statement | Mar 3, 2023 | Apr 10, 2023 |
| DEFA14A | Additional proxy material | May 17, 2022 | — |
| DEFA14A | Additional proxy material | May 2, 2022 | — |
| DEF 14A | Proxy statement | May 2, 2022 | Jun 21, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2022 | Jun 21, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 17, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2021 | Jun 17, 2021 |
| DEFA14A | Additional proxy material | Jun 12, 2020 | — |
| DEFA14A | Additional proxy material | Jun 4, 2020 | — |
| DEFA14A | Additional proxy material | Jun 2, 2020 | — |
| DEFA14A | Additional proxy material | Apr 27, 2020 | — |
| DEF 14A | Proxy statement | Apr 27, 2020 | Jun 17, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2020 | Jun 17, 2020 |
| DEFA14A | Additional proxy material | Apr 30, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 18, 2019 |
| DEFA14A | Additional proxy material | Apr 30, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 14, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2018 | Jun 14, 2018 |
| DEFA14A | Additional proxy material | Apr 26, 2017 | — |
| DEF 14A | Proxy statement | Apr 26, 2017 | Jun 7, 2017 |
| DEFA14A | Additional proxy material | Apr 29, 2016 | — |
| DEF 14A | Proxy statement | Apr 29, 2016 | Jun 16, 2016 |
| DEFA14A | Additional proxy material | Jun 4, 2015 | — |
| DEF 14A | Proxy statement | Jun 4, 2015 | Jul 15, 2015 |
| DEFA14A | Additional proxy material | Apr 30, 2014 | — |
| DEF 14A | Proxy statement | Apr 30, 2014 | Jun 16, 2014 |
| DEF 14A | Proxy statement | Aug 30, 2013 | Sep 30, 2013 |
| PRE 14A | Preliminary proxy statement | Aug 9, 2013 | Sep 30, 2013 |
| DEF 14A | Proxy statement | May 15, 2013 | Jun 19, 2013 |
| DEF 14A | Proxy statement | Jul 13, 2012 | Aug 16, 2012 |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FBIO (Nasdaq), FBIOP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bay Harbor Islands, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1429260
- Former names
- Fortress Biotech, Inc. (until Oct 29, 2026); CORONADO BIOSCIENCES INC (until Apr 27, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.